Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC-1 CAR T cells
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MUC-1 CAR T cells are an immunotherapy consisting of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) specific for Mucin 1 (MUC1). MUC1 is a heavily glycosylated protein that is frequently overexpressed and loses its apical polarization in various adenocarcinomas, making it a viable target for CAR-T therapy in solid tumors. Upon binding to MUC1 on the tumor cell surface, the CAR-T cells undergo activation, proliferation, and exert cytotoxic effects against the cancer cells. Clinical trials, primarily conducted in China, are currently evaluating these therapies in patients with advanced or recurrent solid tumors, including pancreatic and breast cancers.
- Other names
- MUC-1 targeted Chimeric Antigen Receptor T CellsMUC1 targeted Chimeric Antigen Receptor T CellsMUC 1 targeted Chimeric Antigen Receptor T CellsMUC1-CARTMUC-1-CARTMUC 1-CARTMUC1 CAR-TMUC-1 CAR-TMUC 1 CAR-T
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)MUC1 (Mucin-1 Antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MUC-1 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC-1 CAR T cells.